Once-daily budesonide in mild asthma

Area of Science:

• Pulmonology
• Pharmacology

Background:

• Inhaled corticosteroid therapy is crucial for chronic asthma management.
• Current recommendations favor twice-daily dosing for mild to moderate asthma.
• Patient compliance with twice-daily regimens can be challenging, potentially impacting disease control.

Purpose of the Study:

• To evaluate the efficacy of once-daily budesonide (0.2 mg via Turbuhaler) compared to twice-daily administration (0.1 mg per dose) in mild to moderate asthma patients.
• To determine if a simplified dosing regimen maintains therapeutic effectiveness.

Main Methods:

• A randomized, double-blind, parallel-group study involving 76 adult patients with mild to moderate asthma.
• Patients received budesonide once daily (0.2 mg) or twice daily (0.1 mg per dose) for 8 weeks after a 2-week run-in period.
• Efficacy assessed via peak expiratory flow (PEF), symptom scores, and beta-2-agonist use, with a 4-week steroid-free washout period.

Main Results:

• Both once-daily and twice-daily budesonide groups showed minimal improvements in peak flow, with no significant differences between groups.
• Clinical equivalence was demonstrated, with 90% confidence intervals for PEF change within clinically relevant limits (+30 to -30 L/min).
• No significant differences were observed in symptom scores, beta-2-agonist usage, or spirometry between the dosing regimens.

Conclusions:

• Once-daily administration of 0.2 mg budesonide is as effective as 0.1 mg twice daily in managing mild to moderate asthma.
• Simplified inhaled corticosteroid dosing may improve compliance without compromising asthma control.
• The study supports the potential for once-daily budesonide therapy as a viable alternative for asthma management.